Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2007.14.1226 on October 22 2007

Journal of Clinical Oncology, Vol 25, No 34 (December 1), 2007: pp. 5506-5518
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pisters, K. M.W.
Right arrow Articles by Shepherd, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pisters, K. M.W.
Right arrow Articles by Shepherd, F. A.

ASCO SPECIAL ARTICLE

Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline

Katherine M.W. Pisters, William K. Evans, Christopher G. Azzoli, Mark G. Kris, Christopher A. Smith, Christopher E. Desch{dagger}, Mark R. Somerfield, Melissa C. Brouwers, Gail Darling, Peter M. Ellis, Laurie E. Gaspar, Harvey I. Pass, David R. Spigel, John R. Strawn, Yee C. Ung, Frances A. Shepherd

From the M.D. Anderson Cancer Center, Houston, TX; Memorial Sloan-Kettering Cancer Center; New York University School of Medicine, New York, NY; National Comprehensive Cancer Network, Jenkintown, PA; American Society of Clinical Oncology, Alexandria, VA; University of Colorado at Denver Health Sciences Center, Denver, CO; National Cancer Institute Cancer Center, Bethesda, MD; Sarah Cannon Cancer Center, Nashville, TN; Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton; Cancer Care Ontario; Toronto-Sunnybrook Regional Cancer Centre; and the University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
{dagger} Deceased.

Address reprint requests to ASCO, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org

Purpose: To determine the role of adjuvant chemotherapy and radiation therapy in patients with completely resected stage IA-IIIA non–small-cell lung cancer (NSCLC).

Methods: The Cancer Care Ontario Program in Evidence-Based Care and the American Society of Clinical Oncology convened a Joint Expert Panel in August 2006 to review the evidence and draft recommendations for these therapies.

Results: Available data support the use of adjuvant cisplatin-based chemotherapy in completely resected NSCLC; however, the strength of the data and consequent recommendations vary by disease stage. Adjuvant radiation therapy appears detrimental to survival in stages IB and II, with a possible modest benefit in stage IIIA.

Conclusion: Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA disease. Although there has been a statistically significant overall survival benefit seen in several randomized clinical trials (RCTs) enrolling a range of people with completely resected NSCLC, results of subset analyses for patient populations with stage IB disease were not significant, and adjuvant chemotherapy in stage IB disease is not currently recommended for routine use. To date, very few patients with stage IA NSCLC have been enrolled onto RCTs of adjuvant therapy; adjuvant chemotherapy is not recommended in these cases. Evidence from RCTs demonstrates a survival detriment for adjuvant radiotherapy with limited evidence for a reduction in local recurrence. Adjuvant radiation therapy appears detrimental to survival in stage IB and II, and may possibly confer a modest benefit in stage IIIA.

published online ahead of print at www.jco.org on October 22, 2007.

This article is dedicated to Christopher E. Desch, MD, who was the National Medical Director of the National Comprehensive Cancer Network, one of the founding volunteers of the Quality Oncology Practice Initiative for ASCO, and a driving force behind ASCO oncology guidelines. As both an academic and community oncologist, he had a unique perspective, ability, and passion to improve the quality of cancer care.

Approved by the ASCO Board of Directors on August 15, 2007.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
W. Zhong, X. Yang, J. Bai, J. Yang, C. Manegold, and Y. Wu
Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer.
Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 187 - 195.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online